Literature DB >> 3739647

Spironolactone in the treatment of hirsutism.

M G Chapman, M Katz, M Dowsett, W Hague, S L Jeffcoate, C J Dewhurst.   

Abstract

Spironolactone (100 mg) for 25 days in each menstrual cycle was assessed over 6 months for treatment of hirsutism in 35 patients. Five patients withdrew due to either nausea or polymenorrhea. the latter problem was encountered in 16 patients. Of the 30 remaining patients, 17 had a significant reduction in hair growth as assessed by Ferriman and Gallwey hair scores (p less than 0.05). The only significant change in endocrine parameters was a reduction in serum testosterone (p less than 0.05). Treatment with spironolactone alone was inferior to our previous experience with the cyproterone acetate--estrogen combination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3739647     DOI: 10.3109/00016348609157358

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

Review 1.  The role of androgen and androgen receptor in skin-related disorders.

Authors:  Jiann-Jyh Lai; Philip Chang; Kuo-Pao Lai; Lumin Chen; Chawnshang Chang
Journal:  Arch Dermatol Res       Date:  2012-07-25       Impact factor: 3.017

Review 2.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

3.  Endocrine and clinical effects of spironolactone in female hyperandrogenism.

Authors:  R Siegberg; P Ylöstalo; T Laatikainen; R Pelkonen; U H Stenman
Journal:  Arch Gynecol       Date:  1987
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.